
The Development of Anticoagulants

BAYER E R



References: 1) Ansell J, et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004. 126 (3 Suppl): 204S-233S 2) Hirsh J, Anand SS, Halperin JL, et al. Guide to anticoagulant therapy: Heparin : a statement for healthcare professionals from the American Heart Association. Circulation. 2001;103,(24):294-3018 3) Graff J, Harder S. Anticoagulant therapy with the oral direct factor Xa inhibitors Rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment. Clin Pharmacokinet. 2013; 52(4) 243-54 4) Lee CJ, Ansell JE. Direct thrombin inhibitors, BJCP. 2011. 72(4) 581-592 5) Cohen AT, Imfeld S, et al. Phase III Trials of New Oral Anticoagulants in the Acute Treatment and Secondary Prevention of VTE: Comparison and Critique of Study Methodology and Results. Adv Ther (2014) 31:473–493 6) Xarelto Summary of Product Characteristics as approved by the European Commission 7) IMS Health MIDAS, Database: Monthly Sales January 2015.